1,731 results match your criteria Nonseminomatous Testicular Tumors


Clinicopathologic features, outcomes, and prognostic factors of testicular sarcoma: a population-based study.

Int Urol Nephrol 2021 Feb 7;53(2):257-267. Epub 2020 Sep 7.

Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Palo Alto, CA, 94305, USA.

Purpose: To describe clinical characteristics and identify prognostic factors among men with testicular sarcoma, and to compare survival with other testicular cancers.

Methods: The surveillance, epidemiology, and end results (SEER) database (1975-2016) was queried to identify adults with testicular sarcoma. Multivariable Cox proportional hazards, Fine and Gray competing-risks regression, propensity score matching, and Kaplan-Meier analyses were used. Read More

View Article and Full-Text PDF
February 2021

Management of Metastatic Pure Teratoma in Chemotherapy Naive Patients With Testicular Primaries.

Am J Clin Oncol 2020 10;43(10):690-693

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN.

Introduction: Patients diagnosed with stage II nonseminomatous germ cell tumors (NSGCT) often receive chemotherapy as primary treatment which exposes patients to immediate and long-term risks of chemotherapy. These risks can be avoided by proceeding to primary retroperitoneal lymph node dissection (RPLND) when a high suspicion of pure metastatic teratoma in the retroperitoneum (RP) exists. We propose that all stage II NSGCT patients with pure testicular teratoma, normal serum tumor markers, and with RP cystic metastases on imaging can safely be treated with primary RPLND. Read More

View Article and Full-Text PDF
October 2020

Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital.

Cancer 2020 10 10;126(19):4362-4370. Epub 2020 Aug 10.

Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.

Background: The objective of this study was to determine whether standardized treatment of germ cell tumors (GCTs) could overcome sociodemographic factors limiting patient care.

Methods: The records of all patients undergoing primary treatment for GCTs at both a public safety net hospital and an academic tertiary care center in the same metropolitan area were analyzed. Both institutions were managed by the same group of physicians in the context of multidisciplinary cancer care. Read More

View Article and Full-Text PDF
October 2020

Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.

BMC Cancer 2020 Aug 5;20(1):728. Epub 2020 Aug 5.

Department of Pathology, Lab. for Exp. Patho-Oncology (LEPO), Erasmus MC-University Medical Center Rotterdam, Cancer Institute, Doctor Molewaterplein 40, 3015, GD, Rotterdam, the Netherlands.

Background: Better biomarkers for assessing risk of relapse in stage I testicular germ cell tumor patients are needed, to complement classical histopathological variables. We aimed to assess the prognostic value of previously suggested biomarkers, related to proliferation (MIB-1 and TEX19) and to immune microenvironment (CXCL12, CXCR4, beta-catenin and MECA-79) in a surveillance cohort of stage I testicular germ cell tumor patients.

Methods: A total of 70 patients were included. Read More

View Article and Full-Text PDF

Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort.

Eur Urol Focus 2020 Jul 15. Epub 2020 Jul 15.

NYU Langone Health, New York, NY, USA.

Background: Primary robot-assisted retroperitoneal lymph node dissection (RA-RPLND) for men with nonseminomatous germ cell tumor (NSGCT) is an alternative to open RPLND for stage I and select stage II patients.

Objective: To report the complication rates and oncologic outcomes from a multi-institutional series, and to estimate reduction in chemotherapy by using upfront minimally invasive surgery.

Design, Setting, And Participants: A retrospective chart review of men undergoing primary robot-assisted RPLND between 2014 and 2019 in five institutions by eight urologists experienced in testis cancer and robotic surgery. Read More

View Article and Full-Text PDF

Posterior retroperitoneoscopic resection of recurrent nonseminomatous tumor mass: a case report of the surgical procedure.

J Surg Case Rep 2020 Jul 8;2020(7):rjaa122. Epub 2020 Jul 8.

Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, The Netherlands.

Treatment of stage II-IV nonseminomatous testicular germ cell tumors (NSTGCTs) consists of cisplatin-based combination chemotherapy and, when present, resection of residual retroperitoneal tumor mass (RRTM) by conventional laparotomy or laparoscopy. In case of a retroperitoneal recurrence, a second conventional or laparoscopic procedure may be challenging. A case of late relapse after prior conventional resection of a RRTM and tailor-made surgical management with a posterior retroperitoneoscopic resection (PRR) is reported. Read More

View Article and Full-Text PDF

Distinct Proteomic Profile of Spermatozoa from Men with Seminomatous and Non-Seminomatous Testicular Germ Cell Tumors.

Int J Mol Sci 2020 Jul 8;21(14). Epub 2020 Jul 8.

American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.

Testicular germ cell tumors (TGCTs) are predominant in young males (15-44 years). Seminomatous and non-seminomatous TGCTs account for about 98% of all TGCTs cases. In this study, we aimed to compare the sperm proteome of patients with seminomatous and non-seminomatous TGCTs to identify possible protein biomarkers that could help distinguish between them in a non-invasive manner. Read More

View Article and Full-Text PDF

Reply to L.H. Einhorn et al.

J Clin Oncol 2020 09 7;38(26):3074-3075. Epub 2020 Jul 7.

Deaglan McHugh, MD, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Department of Medicine, Weill Medical College of Cornell University, New York, NY; George J. Bosl, MD, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and Samuel A. Funt, MD and Darren R. Feldman, MD, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Medical College of Cornell University, New York, NY.

View Article and Full-Text PDF
September 2020

Adjuvant Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors: Is This the Preferred Option?

J Clin Oncol 2020 09 7;38(26):3073-3074. Epub 2020 Jul 7.

Lawrence H. Einhorn, MD; Nabil Adra, MD; and Nasser Hanna, MD, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; and Craig Nichols, MD, SWOG Chair's Office and Testicular Cancer Commons, Portland, OR.

View Article and Full-Text PDF
September 2020

Current Insights into Interethnic Variability in Testicular Cancers: Population Pharmacogenetics, Clinical Trials, Genetic Basis of Chemotherapy- Induced Toxicities and Molecular Signal Transduction.

Curr Top Med Chem 2020 ;20(20):1824-1838

SVKM's Dr. Bhanuben Nanavati College of Pharmacy, University of Mumbai, V. L. Mehta Road, Vile Parle (West), Mumbai - 400 056, India.

Testicular cancer is an aggressive malignancy with a rising incidence rate across the globe. Testicular germ cell tumors are the most commonly diagnosed cancers, and surgical removal of the testes is often a radical necessity along with chemotherapy and radiotherapy. While seminomas are receptive to radiotherapy as well as chemotherapy, non-seminomatous germ cell tumors respond to chemotherapy only. Read More

View Article and Full-Text PDF

HIF1α inhibitor 2-methoxyestradiol decreases NRN1 expression and represses in vivo and in vitro growth of patient-derived testicular germ cell tumor spheroids.

Cancer Lett 2020 10 13;489:79-86. Epub 2020 Jun 13.

Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, 350-1241, Japan; Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo, 173-0015, Japan. Electronic address:

Testicular germ cell tumor (GCT) is the most common type of malignancy in young males. Patients with nonseminomatous GCT still have poor prognosis. To identify new therapeutic targets, we generated patient-derived cells (PDCs) and their xenograft (PDCX) models from 3 distinct GCT patients' specimens. Read More

View Article and Full-Text PDF
October 2020

An Abdominal Tumor of Unknown Origin: Acknowledging a Failure to Descend on the Correct Diagnosis.

Gastroenterology 2020 11 6;159(5):1665-1666. Epub 2020 Jun 6.

Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:

View Article and Full-Text PDF
November 2020

Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.

Urol Oncol 2020 08 21;38(8):687.e19-687.e23. Epub 2020 May 21.

Indiana University School of Medicine, Indianapolis, IN.

Purpose: Choriocarcinoma germ cell tumors are rare and usually present with significantly elevated human chorionic gonadotropin (hCG) levels. When curable, it is felt to be largely a result of chemotherapy. We sought to determine the histologic characteristics for those undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) and compare them with metastatic nonseminomatous germ cell tumor (NSGCT) patients with similarly elevated hCG levels. Read More

View Article and Full-Text PDF

Incident testicular cancer in relation to using marijuana and smoking tobacco: A systematic review and meta-analysis of epidemiologic studies.

Urol Oncol 2020 07 12;38(7):642.e1-642.e9. Epub 2020 May 12.

Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA; Department of Obstetrics and Gynecology, Keck School of Medicine of USC, Los Angeles, CA. Electronic address:

Background: Recent epidemiologic studies identified credible associations between marijuana smoking and risk of nonseminomatous testicular germ cell tumors (TGCTs), but did not distinguish exposure to cannabinoid compounds from exposure to other constituents of smoke.

Methods: We implemented a systematic review of scholarly literature followed by random effects meta-analysis to quantitatively synthesize published data relating incident TGCT to each of 2 exposure histories: ever using marijuana, and ever smoking tobacco.

Results: We identified four epidemiologic studies of marijuana use and 12 of tobacco smoking. Read More

View Article and Full-Text PDF

Unusual Chemotherapeutic Resistant Testicular Embryonal Germ Cell Tumor with Widespread Metastasis in a Case of Klinefelter Syndrome: A Case Report.

Cureus 2020 Apr 11;12(4):e7637. Epub 2020 Apr 11.

Medical Oncology, Larkin Community Hospital, Miami, USA.

Cryptorchidism is an undeniable risk factor for testicular germ cell tumors (TGCTs) and is also commonly associated with Klinefelter syndrome (KS) patients. Embryonal cell carcinoma usually shows strong expression of CD30 and OCT3/4, with patchy staining of PLAP1. Most patients with nonseminomatous GCTs (NSGCTs) can achieve total remission with proactive chemotherapy, and most can be cured. Read More

View Article and Full-Text PDF

Editorial Comment to Prediction models for the viability of pulmonary metastatic lesions after chemotherapy in nonseminomatous germ cell tumors.

Authors:
Takeshi Kishida

Int J Urol 2020 05 27;27(5):474. Epub 2020 Apr 27.

Department of Urology, Kanagawa Cancer Center Hospital, Yokohama, Kanagawa, Japan.

View Article and Full-Text PDF

National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.

Urol Oncol 2020 08 15;38(8):687.e13-687.e18. Epub 2020 Apr 15.

Section of Urology, University of Chicago Medicine, Chicago, IL.

Introduction: For marker-negative clinical stage (CS) IIA nonseminomatous germ cell tumor (NSGCT), National Comprehensive Cancer Network and American Urological Association guidelines recommend either retroperitoneal lymph node dissection (RPLND) or induction chemotherapy. The goal is cure with one form of therapy. We evaluated national practice patterns in the management of CSIIA NSGCT and utilization of secondary therapies. Read More

View Article and Full-Text PDF

Incidence and long-term effects of treatment of malignant germ cell neoplasms in Ukraine.

Exp Oncol 2020 03;42(1):66-74

National Cancer Registry of Ukraine, National Cancer Institute, Kyiv 03022, Ukraine.

Aim: To describe incidence of malignant germ cell neoplasms (GCNs) in Ukraine and assess the medical care to patients with GCNs and its efficacy.

Materials And Methods: Records on 6495 males and 1038 females with malignant GCNs diagnosed in 2000-2013 extracted from the database of National Cancer Registry of Ukraine have been analyzed using methods of descriptive epidemiology and survival evaluation.

Results: In Ukraine, GCNs covered 79. Read More

View Article and Full-Text PDF

Utilization of robotics for retroperitoneal lymph-node dissection in pediatric and non-pediatric hospitals.

J Robot Surg 2020 Dec 21;14(6):865-870. Epub 2020 Mar 21.

Division of Urology at Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA.

The objective of this study is to determine recent trends in use of robotics and laparoscopy for pediatric retroperitoneal lymph-node dissection (RPLND) in pediatric and non-pediatric hospitals. We conducted a retrospective cohort study using data from 29 hospitals in the Pediatric Health Information System (PHIS), and data from 14 states in the State Inpatient Databases (SID), between 2008 and 2014. The study population was comprised of patients aged ≥ 10 years undergoing RPLND, with an inpatient diagnosis of testicular or paratesticular cancer, based on international classification of disease (ICD) codes. Read More

View Article and Full-Text PDF
December 2020

Clinical outcome of post-chemotherapy retroperitoneal lymph node dissection in metastatic nonseminomatous germ cell tumour: A systematic review.

Eur J Surg Oncol 2020 06 26;46(6):999-1005. Epub 2020 Feb 26.

Dept. of Oncological Urology, University Medical Center Utrecht, Postbox 85500, 3508, GA, Utrecht, the Netherlands. Electronic address:

Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) is an important element of the management of patients with residual tumour after chemotherapy for disseminated nonseminomatous germ cell tumour (NSGCT). This is a challenging procedure and the outcome varies widely between institutions. There is much debate concerning the anatomical extent of the dissection and the literature is conflicting regarding the outcome of this procedure. Read More

View Article and Full-Text PDF

Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.

J Clin Oncol 2020 04 5;38(12):1338-1345. Epub 2020 Mar 5.

Division of Hematology and Medical Oncology, Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN.

Purpose: Presence of teratoma in patients with metastatic testicular germ cell tumor (GCT) is of unknown prognostic significance. We report survival outcomes of patients with or without teratoma in primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimen and assess impact on prognosis.

Patients And Methods: Patients with metastatic nonseminomatous GCT (NSGCT) who were evaluated at Indiana University between 1990 and 2016 and had primary testicular tumor specimen from orchiectomy (ORCH) were included. Read More

View Article and Full-Text PDF

Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors.

J Clin Oncol 2020 04 28;38(12):1332-1337. Epub 2020 Feb 28.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Purpose: The relapse rate after primary retroperitoneal lymph node dissection (RPLND) for patients with pathologic stage (PS) IIA nonseminomatous germ cell tumors (NSGCTs) is 10%-20% but increases to ≥ 50% for PS IIB disease. We report our experience with 2 cycles of adjuvant etoposide plus cisplatin (EP×2) after therapeutic primary RPLND.

Patients And Methods: All patients with PS II NSGCT seen at Memorial Sloan Kettering Cancer Center from March 1989 to April 2016 and who were planned to receive EP×2 were included. Read More

View Article and Full-Text PDF

Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.

Asian Pac J Cancer Prev 2020 Feb 1;21(2):511-515. Epub 2020 Feb 1.

Department of Nuclear Medicine, Kuwait Cancer Control Center, Ministry of Health, Kuwait.

Objectives: The present study aims to evaluate the role of Positron emission tomography (PET) -computed tomography (CT) with 18F-fluorodeoxyglucose (18F-FDG) in the restaging of high-risk testicular cancer.

Methods: Forty-five patients (mean age of 38.1±11. Read More

View Article and Full-Text PDF
February 2020

Meningothelial Meningioma Component in a Prepubertal Testicular Teratoma.

Case Rep Pathol 2020 20;2020:6495321. Epub 2020 Jan 20.

Department of Paediatric Surgery, AIIMS, Patna, India.

Teratomas are nonseminomatous germ cell tumors composed of elements derived from more than one germinal layers (endoderm, mesoderm, and ectoderm). Malignant transformation of teratoma in the testis is well known; however, benign somatic neoplasm arising in a testicular teratoma is a rare occurrence. We report a case of meningothelial variant of meningioma arising in a pure and mature teratoma of the testis in a 5-year-old boy. Read More

View Article and Full-Text PDF
January 2020

Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors.

Transl Androl Urol 2020 Jan;9(Suppl 1):S45-S55

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Early stage nonseminomatous germ cell tumor (NSGCT) remains a treatable disease, with stage I cancer specific survival exceeding 95%. Using a risk-adapted approach; active surveillance (AS), adjuvant chemotherapy, and retroperitoneal lymph node dissection (RPLND) all options for treatment; with surveillance being increasingly used. With persistently elevated markers (stage IS), chemotherapy remains the hallmark of treatment. Read More

View Article and Full-Text PDF
January 2020

Immunohistochemical characterization of the anti-Müllerian hormone receptor type 2 (AMHR-2) in human testes.

Endocrine 2020 04 6;68(1):215-221. Epub 2020 Feb 6.

Centre of Reproductive Medicine and Andrology, University Hospital of Münster, Albert-Schweitzer Campus 1, 48149, Münster, Germany.

Purpose: In males, AMH is secreted by immature Sertoli cells; following exposure to endogenous androgens, Sertoli cells undergo a process of maturation which ultimately inhibits AMH expression to undetectable levels in the serum. However, expression of AMH receptor (AMHR-2) has never been studied in human testes, and high intratubular concentrations of AMH have been reported in recent literature. We therefore assessed expression of AMHR-2 in several testicular tissue samples by immunohistochemistry (IHC). Read More

View Article and Full-Text PDF

Disorder of sex development with germ cell tumors: Which is uncovered first?

Pediatr Blood Cancer 2020 04 4;67(4):e28169. Epub 2020 Feb 4.

Institut de Pathologie Multisite, Groupement hospitalier Est, Hospices Civils de Lyon, UCBL Lyon 1 University, Lyon, France.

Background: Disorders of sex development (DSD) are rare conditions. Although they are known to predispose to germ cell tumors (GCT), there is a paucity of information regarding the circumstances of DSD discovery.

Design/methods: All patients with DSD registered in two French pediatric GCT protocols (TGM95 and 13) were analyzed. Read More

View Article and Full-Text PDF

Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors.

Curr Opin Urol 2020 03;30(2):251-257

Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.

Purpose Of Review: Early-stage testicular cancers are highly curable. Following orchidectomy, management options for stage I disease include active surveillance, nerve-sparing retroperitoneal lymph node dissection (nsRPLND) and primary chemotherapy as recommended by the current guidelines. Primary RPLND has for decades played an integral part of treatment in patients with early-stage testicular germ cell tumors (TGCT), particularly in nonseminomatous germ cell tumors (NSGCT) with focus on reducing the long-term morbidity. Read More

View Article and Full-Text PDF